Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor

William G. Wierda(University of Maryland, Baltimore), Michael Y. Choi(University of California San Diego), Lang Zhou(Qingdao University), Paul M. Barr(University of Rochester Medical Center), Matthew S. Davids(Dana-Farber Cancer Institute), Herbert Eradat(University of Colorado Cancer Center), Bruce D. Cheson(Center for Cancer and Blood Disorders), Jalaja Potluri(AbbVie (United States)), Leonard T. Heffner, John C. Byrd(University of Cincinnati), Maria Verdugo(AbbVie (United States)), Richard R. Furman(Cornell University)
British Journal of Haematology
November 27, 2018
10.1111/bjh.15666
Cited by 15

Related Papers

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k